Article

Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Free Radical Biology and Medicine (Impact Factor: 5.71). 10/2011; 52(1):182-90. DOI: 10.1016/j.freeradbiomed.2011.10.444
Source: PubMed

ABSTRACT Benfotiamine, a lipid-soluble analogue of vitamin B1, is a potent antioxidant that is used as a food supplement for the treatment of diabetic complications. Our recent study (U.C. Yadav et al., Free Radic. Biol. Med. 48:1423-1434, 2010) indicates a novel role for benfotiamine in the prevention of bacterial endotoxin, lipopolysaccharide (LPS)-induced cytotoxicity and inflammatory response in murine macrophages. Nevertheless, it remains unclear how benfotiamine mediates anti-inflammatory effects. In this study, we investigated the anti-inflammatory role of benfotiamine in regulating arachidonic acid (AA) pathway-generated inflammatory lipid mediators in RAW264.7 macrophages. Benfotiamine prevented the LPS-induced activation of cPLA2 and release of AA metabolites such as leukotrienes, prostaglandin E2, thromboxane 2 (TXB2), and prostacyclin (PGI2) in macrophages. Further, LPS-induced expression of AA-metabolizing enzymes such as COX-2, LOX-5, TXB synthase, and PGI2 synthase was significantly blocked by benfotiamine. Furthermore, benfotiamine prevented the LPS-induced phosphorylation of ERK1/2 and expression of transcription factors NF-κB and Egr-1. Benfotiamine also prevented the LPS-induced oxidative stress and protein-HNE adduct formation. Most importantly, compared to specific COX-2 and LOX-5 inhibitors, benfotiamine significantly prevented LPS-induced macrophage death and monocyte adhesion to endothelial cells. Thus, our studies indicate that the dual regulation of the COX and LOX pathways in AA metabolism could be a novel mechanism by which benfotiamine exhibits its potential anti-inflammatory response.

0 Followers
 · 
172 Views
  • Source
    • "Interestingly, LPS-induced inflammatory signals are known to mediate activation of NF-țB through ROS [31]. It has recently been shown that various antioxidants, such as vitamin C and vitamin E, inhibit ROS-induced inflammatory responses by preventing activation of NF-țB [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical evidence demonstrates that ubiquinol-10, the reduced active form of Coenzyme Q10 (CoQ10H2), improves endothelial function through its antioxidant and likely anti-inflammatory properties. We previously reported that a biomarker combination including miR-146a, its target protein IL-1 receptor-associated kinase (IRAK-1), and released interleukin (IL)-6, here collectively designated as MIRAKIL, indicates senescence-associated secretory phenotype (SASP) acquisition by primary human umbilical vein endothelial cells (HUVEC). We explore the ability of short- and long-term CoQ10H2 supplementation to affect MIRAKIL in HUVEC, used as a model of vascular aging, during replicative senescence in absence/presence of lipopolysaccharide (LPS), a proinflammatory stimulus. Senescent HUVEC had the same ability as young cells to internalize CoQ10 and exhibit an improved oxidative status. LPS-induced NF-κB activation diminished after CoQ10H2 pretreatment both in young and senescent cells. However, short-term CoQ10H2 supplementation attenuated LPS-induced MIRAKIL changes in young cells; in senescent cells CoQ10H2 supplementation significantly attenuated LPS-induced miR-146a and IRAK-1 modulation but failed to curb IL-6 release. Similar results were obtained with long-term CoQ10H2 incubation. These findings provide new insights into the molecular mechanisms by which CoQ10H2 stems endothelial cell inflammatory responses and delays SASP acquisition. These phenomena may play a role in preventing the endothelial dysfunction associated with major age-related diseases.
    Free Radical Biology and Medicine 05/2013; 63. DOI:10.1016/j.freeradbiomed.2013.05.033 · 5.71 Impact Factor
  • Source
    • "Thus, it blocks several hyperglycemiainduced pathways, one of them being endogenous AGE and dicarbonyls formation [16]. But benfotiamine has also antioxidant properties [17] [18], protects endothelial cells under conditions of hyperglycemia [19] in vitro and in animal models, modulates the activity of the nitric oxide synthase [20] [21] (NOS, a critical enzyme that promotes nitric oxide generation), has anti-inflammatory effects [22], and protects against smoke induced endothelial dysfunction in rats [23]. Moreover, we and others [24] have previously shown protective effects of benfotiamine or thiamine on endothelial cells in humans postprandially or during hyperglycemia [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Smoking induces endothelial dysfunction (ED) mainly by exacerbating oxidative stress (OS) and inflammation. Benfotiamine, a thiamine prodrug with high bioavailability, prevents nicotine-induced vascular dysfunction in rats. It remained unknown whether this effect also occurs in humans. Methods. Therefore, 20 healthy volunteers (mean age: 38 years) were investigated twice, 7-10 days apart in a randomized, cross-over, and investigator-blinded design. Vascular function was assessed by flow-mediated vasodilatation (FMD) of the brachial artery and by measurements of the soluble vascular cell adhesion molecule (sVCAM)-1. Investigations were performed after an overnight fast as well as 20 minutes after one cigarette smoking. On another day, the same procedure was applied following a 3-day oral therapy with benfotiamine (1050 mg/day). Ten patients were randomized to start with smoking alone, and ten started with benfotiamine. Results. Results are expressed as (mean ± SEM). Smoking acutely induced a decrease in FMD by 50% ((∗∗)P < 0.001 versus baseline) an effect significantly reduced by benfotiamine treatment to 25%(∗§) ((∗)P < 0.05 versus baseline, (§)P < 0.05 versus smoking alone). Smoking-induced elevation in sVCAM-1 was also prevented by benfotiamine. The endothelium-independent vasodilatation remained unaltered between days. Conclusion. In healthy volunteers, smoking blunts vascular function mirrored by a decrease in FMD and an increase in sVCAM-1. Short-term treatment with benfotiamine significantly reduces these effects, showing protective vascular properties.
    International journal of vascular medicine 10/2012; 2012:968761. DOI:10.1155/2012/968761
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine if dietary fat composition affects the progression of nonalcoholic fatty liver disease (NAFLD), male Sprague-Dawley rats were overfed low (5%) or high (70%) fat diets with different fat sources: olive oil (OO), corn oil (CO) or echium oil (EO) using total enteral nutrition (TEN) for 21 d. Overfeeding of the 5% CO diet resulted in less steatosis than 5% OO or 5% EO (p< 0.05). Affymetix array analysis revealed significant differences in hepatic gene expression signatures associated with greater fatty acid synthesis, ChREBP and SREBP-1c signaling and increased fatty acid transport (P<0.05) in the 5% OO compared to 5% CO group. The OO groups had macrosteatosis but no evidence of oxidative stress or necrosis. The 70% CO and 70% EO groups had a mixture of micro- and macrosteatosis or only microsteatosis, respectively; increased oxidative stress; and increased necrotic injury relative to their respective 5% groups (P<0.05). Oxidative stress and necrosis correlated with increasing peroxidizability of the accumulated triglycerides. Affymetix array analysis comparing the 70% OO and 70% CO groups revealed increased antioxidant pathways and lower expression of genes linked to inflammation and fibrosis in the 70% OO group. In a second study where the 70% OO diet was overfed for 50 d, there was no evidence of progression of injury beyond simple steatosis. These data suggest that dietary fat type strongly influences the progression of NAFLD and that a Mediterranean diet high in olive oil may reduce the risk of nonalcoholic steatohepatitis (NASH).
    Physiological Genomics 09/2012; 44(22). DOI:10.1152/physiolgenomics.00069.2012 · 2.81 Impact Factor
Show more

Preview

Download
0 Downloads
Available from